|
A Study of the Effects of Advantage 24 on the Rectum Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on A Study of the Effects of Advantage 24 on the Rectum conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of the Effects of Advantage 24 on the Rectum Clinical research trials and A Study of the Effects of Advantage 24 on the Rectum medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like A Study of the Effects of Advantage 24 on the Rectum. A Study of the Effects of Advantage 24 on the Rectum Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a A Study of the Effects of Advantage 24 on the Rectum clinical trial. Participants frequently obtain the most expert healthcare available for their A Study of the Effects of Advantage 24 on the Rectum condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of the Effects of Advantage 24 on the Rectum  A Study of the Effects of Advantage 24 on the Rectum
A Study of the Effects of Advantage 24 on the Rectum
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Advantage 24 is a spermicide (a chemical that kills sperm). Much research and development is being done with chemicals that can be controlled by the receptive partner to prevent the spread of HIV and other sexually transmitted diseases (STDs). Advantage 24 currently is used in the vagina as a form of birth control. The safety of Advantage 24 is particularly important for HIV-positive men because they have a greater chance of serious reaction to Advantage 24 due to other HIV-related conditions.
Details: Chemical barriers which can be controlled by the receptive partner to prevent transmission of HIV and other sexually transmitted diseases (STDs) are among the highest priorities for research and development. Advantage 24 is a contraceptive gel containing nonoxynol-9 (N-9). This study provides information on the safety of N-9 in a bioadhesive gel formulated for use by MSM during anal intercourse. Safety is assessed for both HIV-positive and HIV-negative men because HIV-positive men may be at increased risk for toxicity due to other HIV-related conditions. Participants are divided into 4 cohorts depending on their serostatus and whether they are the insertive or receptive partner. Participants apply Advantage 24 once or twice a day for 5 weeks and 4 times a day for the sixth week. Check-in visits, which include a genital exam, are performed at Weeks 1, 2, 4, 5, and 7. More complete physical evaluations, including anoscopy for receptive partners and blood tests, are performed at Weeks 3, 6, and 8.
Eligibility:
Study Type: Interventional, Prevention, Dose Comparison, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria: Exclusion Criteria Co-existing Condition: Participants with the following symptoms or conditions are excluded: - Positive HSV-2 serology (HIV-negative participants only). - Positive syphilis by Venereal Disease Research Laboratory (VDRL) serology and Fluorescent Treponemal Antibody (FTA) or Microhemagglutination Assay (MHA). Receptive partners with the following additional symptoms or conditions are excluded: - Rectal gonorrhea or chlamydia by culture. - Active rectal inflammation, ulceration, or fissures. Insertive partners with the following additional symptoms or conditions are excluded: - Penile or urethral irritation, rashes, or lesions. - Penile or scrotal piercing. Concurrent Medication: Excluded for receptive partners: Anticoagulant, including warfarin and heparin. Participants with the following prior conditions are excluded: - Sensitivity or irritative symptoms when using N-9 or when exposed to latex. - Three or more Herpes Simplex 2 Virus (HSV-2) outbreaks within 12 months prior to screening (HIV-positive participants only). - One or more HSV-2 outbreaks within 6 months prior to screening (HIV-positive participants only). Receptive partners with the following additional prior conditions are excluded: - Diagnosed inflammatory bowel disease, ulcerative colitis, Crohn's disease, or rectal malignancy. - Diagnosed bleeding disorder, including hemophilia and thrombocytopenia. - Rectal surgery including fistulectomy. - Prosthetic heart valve or diagnosis of a valvular abnormality. - Hemorrhoidectomy within 6 months prior to screening. - Rectal burning, tenesmus, bleeding, or irritation in the week prior to screening. - Diarrhea (more than 3 stools per day) in the week prior to screening. - Use of rectally-inserted sex toys, practiced receptive fisting, or rectal douching in the week prior to screening. Insertive partners with the following additional prior conditions are excluded: Urethral burning or discharge in the week prior to screening. Prior Medication: Excluded for receptive partners: Use of laxatives in the week prior to screening. Participants meet the following criteria: - HIV-negative or HIV-positive; participant's partner must be the same serostatus. - Plan to have anal intercourse only with the study partner for the duration of the study. During all episodes in which Advantage 24 is used, one partner is exclusively insertive and the other partner is exclusively receptive. - Sexual partner of at least 3 months is eligible and agrees to participate. - Agree to use non-N-9 lubricant and condoms for all episodes of anal intercourse. - Avoid use of Advantage 24 for purposes other than specified by the protocol. Receptive partners meet the following additional criteria: - Plan to have receptive anal intercourse with the study partner with Advantage 24 applied rectally, and using N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week). - Agree to apply the specified amount of Advantage 24 daily to the rectum. - Avoid use of laxatives, use of rectally-inserted sex toys, receptive fisting, and rectal douching. Insertive partners meet the following additional criteria: - Plan to have insertive anal intercourse with the study partner with Advantage 24 applied to the glans of the penis, and using non-N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week). - Agree to apply the specified amount of Advantage 24 daily to the penis.
Total Enrollment: 70
Location and Contact Information:
Overall Study Official:
ConnieCelum, Study Chair,
Univ of Washington
Seattle, Washington, 98104
United States
Additional Information:
Study ID Numbers: HIVNET 008;
Study Start Date:
Record last reviewed: March 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000929
Other Hiv Infections Studies:
1. A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine
2. A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
3. A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients with AIDS Who Cannot Use Ganciclovir
4. An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients
5. HIV Expression in Patients with Low Viral Load on Highly Active Antiretroviral Therapy (HAART)
Related Studies:
Other HIV Infections Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
A Study of the Effects of Advantage 24 on the Rectum
|
|
|
|
|
|
|
|
